Wave Life Sciences (NASDAQ: WVE) SVP reports option exercises and share sales
Rhea-AI Filing Summary
Wave Life Sciences Ltd. executive reports option exercises and share sales. On December 8, 2025, a senior officer of Wave Life Sciences exercised multiple vested share options with exercise prices ranging from $2.83 to $10.48 per ordinary share and sold the resulting shares on the same day. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025.
Following the reported option exercises and sales, the officer directly holds 25,000 ordinary shares. The filing notes that certain sale prices are reported on a weighted-average basis, including averages of $14.556 and $14.195 per share, and the officer has agreed to provide full pricing details upon request.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (right to buy) | 75,000 | $0.00 | -- |
| Exercise | Share Option (right to buy) | 125,300 | $0.00 | -- |
| Exercise | Share Option (right to buy) | 168,231 | $0.00 | -- |
| Exercise | Share Option (right to buy) | 50,000 | $0.00 | -- |
| Exercise | Share Option (right to buy) | 22,500 | $0.00 | -- |
| Exercise | Ordinary Shares | 28,125 | $3.14 | $88K |
| Sale | Ordinary Shares | 28,125 | $14.50 | $408K |
| Exercise | Ordinary Shares | 107,400 | $3.87 | $416K |
| Sale | Ordinary Shares | 107,400 | $14.556 | $1.56M |
| Exercise | Ordinary Shares | 45,882 | $4.75 | $218K |
| Sale | Ordinary Shares | 45,882 | $14.50 | $665K |
| Exercise | Ordinary Shares | 9,375 | $3.14 | $29K |
| Sale | Ordinary Shares | 9,375 | $15.00 | $141K |
| Exercise | Ordinary Shares | 37,500 | $3.14 | $118K |
| Sale | Ordinary Shares | 37,500 | $14.08 | $528K |
| Exercise | Ordinary Shares | 17,900 | $3.87 | $69K |
| Sale | Ordinary Shares | 17,900 | $15.00 | $269K |
| Exercise | Ordinary Shares | 122,349 | $4.75 | $581K |
| Sale | Ordinary Shares | 122,349 | $14.195 | $1.74M |
| Exercise | Ordinary Shares | 50,000 | $10.48 | $524K |
| Sale | Ordinary Shares | 50,000 | $16.00 | $800K |
| Exercise | Ordinary Shares | 22,500 | $2.83 | $64K |
| Sale | Ordinary Shares | 22,500 | $14.08 | $317K |
Footnotes (1)
- The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. The share option represented a right to purchase a total of 150,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. The share option represented a right to purchase a total of 286,400 ordinary shares that vest as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.50 to $14.78 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The share option represented a right to purchase a total of 244,700 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.08 to $15.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. These share options are fully vested.
FAQ
What insider transaction did Wave Life Sciences (WVE) report in this Form 4?
The filing shows a senior officer of Wave Life Sciences Ltd. (WVE) exercised multiple vested share options and sold the resulting ordinary shares on December 8, 2025, while retaining 25,000 ordinary shares directly.
Which Wave Life Sciences executive is involved and what is their role?
The reporting person is an officer of Wave Life Sciences serving as SVP, Corporate Development, Head of Emerging Areas, and is identified as an officer of the issuer in the filing.
Were the Wave Life Sciences (WVE) insider trades made under a Rule 10b5-1 plan?
Yes. The filing states that the option exercises and related sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
What option exercise prices are disclosed for the Wave Life Sciences (WVE) insider?
The officer exercised share options with exercise prices of $2.83, $3.14, $3.87, $4.75, and $10.48 per ordinary share, as detailed in the derivative securities table.
Does the Wave Life Sciences (WVE) insider still hold options after these transactions?
Yes. The derivative securities table shows that the officer continues to hold share options that remain beneficially owned after the reported exercises and sales, in addition to directly held shares.
